SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced results of studies on its investigational, multi-targeted kinase inhibitor – AP24534 – showing complete inhibition of all known mutant variants of the target protein, Bcr-Abl, including the T315I mutant that is resistant to currently marketed therapies for chronic myeloid leukemia (CML). Investigators from the Oregon Health & Science University Cancer Institute and the Howard Hughes Medical Institute, collaborating with ARIAD scientists, presented the data yesterday evening at the 50th American Society of Hematology (ASH) Annual Meeting.
